Visão geral da empresa
BioVie Inc. operates as a clinical-stage biopharmaceutical entity dedicated to developing proprietary drug therapies aimed at treating neurological, neurodegenerative disorders, and advanced liver disease within the United States market. The company functions within the broader Healthcare sector, specifically targeting the specialized Biotechnology industry, a classification that denotes a focus on early-stage research and development of innovative medical treatments rather than established commercial products. Its operational scale is defined by a market capitalization of $10.86 million, a team comprising 13 employees, and currently reported revenue figures that are not available for the trailing twelve-month period. These valuation and staffing metrics suggest the company is in a nascent growth phase, where capital allocation is heavily weighted toward advancing its pipeline assets, such as BIV201, which is in phase 2 for the treatment of ascites due to chronic liver cirrhosis, rather than generating substantial commercial revenue streams or maintaining a large workforce typical of mature pharmaceutical firms.
Saúde financeira
The financial performance for the trailing twelve months shows revenue figures listed as not available, while the company recorded a net income of $-17,478,136 and an EBITDA of $-17,968,812, indicating significant operational losses driven by the high costs associated with clinical trials and research and development activities. The gap between the unquantified revenue and the substantial net loss reveals a cost structure dominated by non-recurring or developmental expenses rather than the cost of goods sold typical of manufacturing businesses, as evidenced by the zero gross margin. The company generated a free cash flow of $-8,277,755, which reflects a burn rate that constrains immediate financial flexibility but is often necessary for clinical-stage entities to reach commercialization milestones. All three margin metrics—gross margin, operating margin, and profit margin—are reported at 0.0%, which signifies that the company has not yet achieved profitability and is operating in a phase where all revenue is consumed by overhead and direct costs. On the balance sheet, the company holds $20.54 million in cash against $314,915 in debt, resulting in a debt-to-equity ratio of 1.64, which presents a leveraged profile relative to its equity base despite the low absolute debt amount. The current ratio stands at 7.25, a figure that indicates robust short-term liquidity and a strong capacity to meet obligations due to the significant cash reserves relative to current liabilities. Furthermore, the return on equity is -80.7% and the return on assets is -47.2%, metrics that reveal that management effectiveness in generating profit from shareholder capital and assets is currently negative, a common characteristic of companies investing heavily in future growth rather than returning value through earnings.
Avaliação de valorização
The trailing P/E ratio is not available due to the lack of net income, while the forward P/E is listed at -0.33, a negative figure that implies the market expects earnings to remain negative or that the valuation model is based on anticipated future profitability rather than historical performance. The price-to-book ratio is 0.56, suggesting that the stock is trading at a discount to its book value, which can indicate either market undervaluation or concerns regarding the quality of the company's assets and future earnings potential. Alternative valuation metrics include a price-to-sales ratio that is not available and an EV/EBITDA of 0.52, figures that suggest the company is valued based on enterprise value relative to its earnings before interest, taxes, depreciation, and amortization, even though those earnings are currently negative. The stock has exhibited volatility with a 52-week high of $13.20 and a 52-week low of $1.06, and without a specific current price in the provided facts, the trading range demonstrates a wide spread typical of small-cap biotechnology stocks. The beta value of 0.56 indicates that the stock's price volatility is lower than that of the broader market, suggesting it may be less sensitive to general market fluctuations than larger-cap equities, although the high volatility within its own trading range suggests specific sector risks.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both listed as not available, preventing a direct comparison of earnings growth relative to revenue growth rates in the current reporting period. The company does not pay a dividend, as indicated by a dividend yield of N/A and a payout ratio of 0.0%, which means the company reinvests all available capital and earnings back into its operations and research initiatives rather than distributing income to shareholders. Given the significant net losses and the absence of a payout ratio, the company's financial strategy focuses entirely on funding its clinical development pipeline and operational expansion rather than providing income returns to investors. The overall growth and income profile for BioVie Inc. is characterized by a complete lack of current profitability and dividend distribution, relying solely on its cash reserves to fund future development and eventual market entry for its therapeutic candidates.